ESR1 and breast carcinoma: Of the breast cancer cases for whom receptor status data were available, the distribution of ER+ and PR+ but not HER2+ was similar to that reported by the Tuscany Cancer Registry among all the invasive breast cancer cases diagnosed during the period 2004–2005 (Caldarella et al. 2011).